Objective: To assess the impact of diagnostic ureteroscopy (URS) prior to radical nephroureterectomy (RNU) on intravesical recurrence (IVR) in patients with upper tract urothelial carcinoma (UTUC). Materials and Methods: A systematic literature search of the Medline, Embase, PubMed, and Cochrane library was performed in August 2017. Cumulative analyses of available hazard ratios (HRs) and their 95% CI were conducted using Stata version 12.0. Results: Eleven studies including 4,057 participants were included, with a total of 1,403 patients diagnosed with IVR during the follow-up period. The pooled HRs of eight studies suggested that diagnostic URS prior to RNU significantly increased the IVR risk after RNU (HR 1.53, 95% CI 1.31–1.77; p < 0.001). However, the preoperative diagnostic URS was not associated with cancer-specific survival (HR 0.72; p = 0.11), metastasis-free survival (HR 1.09; p = 0.60) or overall survival (HR 1.12; p = 0.73). No publication bias was observed (Begg, p = 0.90; Egger, p = 0.71). Conclusions: Regardless, the diagnostic URS prior to RNU might increase the IVR risk in patients with UTUC. As ureteroscopy provides important prognostic and therapeutic value and guides decisions in UTUC, more future studies should be performed to find a novel way to mitigate the potential risk of IVR after RNU, such as chemoprophylaxis after endoscopy.

Keywords:
Upper urinary tract, Urothelial carcinoma, Ureteroscopy, Intravesical recurrence, Nephroureterectomy
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10–29.
2.
Redrow GP, Matin SF: Upper tract urothelial carcinoma: epidemiology, high risk populations and detection. Minerva Urol Nefrol 2016; 68: 350–358.
3.
Novara G, De Marco V, Dalpiaz O, et al: Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int 2008; 101: 1368–1374.
4.
Xylinas E, Colin P, Audenet F, et al: Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol 2013; 31: 61–68.
5.
Seisen T, Granger B, Colin P, et al: A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015; 67: 1122–1133.
6.
Rouprêt M, Babjuk M, Compérat E, et al: European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015; 68: 868–879.
7.
Potretzke AM, Knight BA, Potretzke TA, Larson JA, Bhayani SB: Is ureteroscopy needed prior to nephroureterectomy? An evidence-based algorithmic approach. Urology 2016; 88: 43–48.
8.
Yoo S, You D, Song C, et al: Risk of intravesical recurrence after ureteroscopic biopsy for upper tract urothelial carcinoma: does the location matter? J Endourol 2017; 31: 259–265.
9.
Sankin A, Tin AL, Mano R, et al: Impact of ureteroscopy before nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes. Urology 2016; 94: 148–153.
10.
Liu P, Su XH, Xiong GY, Li XS, Zhou LQ: Diagnostic ureteroscopy for upper tract urothelial carcinoma is independently associated with intravesical recurrence after radical nephroureterectomy. Int Braz J Urol 2016; 42: 1129–1135.
11.
Sung HH, Jeon HG, Han DH, et al: Diagnostic ureterorenoscopy is associated with increased intravesical recurrence following radical nephroureterectomy in upper tract urothelial carcinoma. PLoS One 2015; 10:e0139976.
12.
Nison L, Rouprêt M, Bozzini G, et al: The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database. World J Urol 2013; 31: 69–76.
13.
Luo HL, Kang CH, Chen YT, et al: Diagnostic ureteroscopy independently correlates with intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Ann Surg Oncol 2013; 20: 3121–3126.
14.
Ishikawa S, Abe T, Shinohara N, et al: Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract. J Urol 2010; 184: 883–887.
15.
Boorjian S, Ng C, Munver R, et al: Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. Urology 2005; 66: 283–287.
16.
Hendin BN, Streem SB, Levin HS, Klein EA, Novick AC: Impact of diagnostic ureteroscopy on long-term survival in patients with upper tract transitional cell carcinoma. J Urol 1999; 161: 783–785.
17.
Lee JK, Kim KB, Park YH, et al: Correlation between the timing of diagnostic ureteroscopy and intravesical recurrence in upper tract urothelial cancer. Clin Genitourin Cancer 2016; 14:e37–e41.
18.
Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815–2834.
19.
Lo CK, Mertz D, Loeb M: Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol 2014; 14: 45.
20.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
21.
Dong JY, Zhang YH, Tong J, Qin LQ: Depression and risk of stroke: a meta-analysis of prospective studies. Stroke 2012; 43: 32–37.
22.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
23.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.
24.
Lee CH, Ku JY, Jeong CW, et al: Predictors for intravesical recurrence following radical nephroureterectomy for upper tract urothelial carcinoma: a national multicenter analysis. Clin Genitourin Cancer 2017;pii:S1558-7673(17)30206-9.
25.
Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH: Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol 1997; 157: 33–37.
26.
Brown GA, Matin SF, Busby JE, et al: Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 2007; 70: 252–256.
27.
Smith AK, Stephenson AJ, Lane BR, et al: Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 2011; 78: 82–86.
28.
Kang CH, Yu TJ, Hsieh HH, et al: The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003; 98: 1620–1626.
29.
Chen MK, Ye YL, Zhou FJ, et al: Clipping the extremity of ureter prior to nephroureterectomy is effective in preventing subsequent bladder recurrence after upper urinary tract urothelial carcinoma. Chin Med J (Engl) 2012; 125: 3821–3826.
30.
Sfakianos JP, Cha EK, Iyer G, et al: Genomic characterization of upper tract urothelial carcinoma. Eur Urol 2015; 68: 970–977.
31.
Yamany T, van Batavia J, Ahn J, Shapiro E, Gupta M: Ureterorenoscopy for upper tract urothelial carcinoma: how often are we missing lesions? Urology 2015; 85: 311–315.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.